The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APGE | +54.6% | N/A | N/A | +212% |
| S&P | +11% | +85.61% | +13.15% | +47% |
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.40M | -733.3% |
| Market Cap | $2.37B | -31.1% |
| Market Cap / Employee | $12.08M | 0.0% |
| Employees | 196 | 0.0% |
| Net Income | -$65.02M | -32.6% |
| EBITDA | -$70.88M | -20.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $107.91M | -9.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.77M | -37.7% |
| Short Term Debt | $4.08M | 42.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.18% | -11.8% |
| Return On Invested Capital | -25.05% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$54.26M | -25.4% |
| Operating Free Cash Flow | -$54.26M | -27.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.61 | 3.10 | 3.84 | 3.82 | -11.18% |
| Price to Tangible Book Value | 3.61 | 3.10 | 3.84 | 3.82 | -11.18% |
| Enterprise Value to EBITDA | -28.83 | -26.60 | -28.08 | -25.64 | -46.72% |
| Return on Equity | -33.2% | -27.9% | -34.1% | -38.4% | 49.77% |
| Total Debt | $11.83M | $11.82M | $10.85M | $9.85M | -18.84% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
